Leap Therapeutics

Closed
47 Thorndike St Ste B1-1
Cambridge, MA 02141

Leap Therapeutics, based in Cambridge, MA, is dedicated to developing targeted and immuno-oncology therapeutics, with a focus on innovative treatments for various cancer types, including gastric, colorectal, and gynecologic cancers. Their lead candidate, DKN-01, is a humanized monoclonal antibody that targets the Dickkopf-1 (DKK1) protein and is currently in clinical development for patients with DKK1-expressing tumors.

In addition to DKN-01, Leap Therapeutics is advancing FL-301, which targets Claudin18.2 for gastric and pancreatic cancers, and FL-501, a preclinical candidate that targets the growth and differentiation factor 15 (GDF-15) protein. The company is committed to understanding tumor expression and discovering new therapeutic targets and combinations to improve cancer treatment outcomes.

Generated from the website

Own this business?
See a problem?

You might also like

United StatesMassachusettsCambridgeLeap Therapeutics

Partial Data by Infogroup (c) 2025. All rights reserved.